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Microencapsulation of active molecules in biocompatible polymers is a matter of
great interest in pharmaceutical sciences. Ultrasonic assisted atomization as a new tech-
nique to produce microencapsulated systems seems to offer several advantages (low
level of mechanical stress in materials, reduced energy request, reduced apparatuses size)
with respect to more conventional techniques.
In this work, fine drug-loaded particles were produced by ionic reticulation of drop-
lets obtained by ultrasonic atomization of biopolymers solutions. The particles were then
characterized in terms of morphology and drug release kinetics. Data were used to esti-
mate the PNMS (Polymeric Network Mesh-Size) with the aims of clarifying its role in
controlled drug release, and analyzing its relationships with material and process param-
eters.
For materials and operative conditions investigated, the calculated PNMS was
found consistent with a fast release of drugs of small molecular size.
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Introduction
Current approaches in the production of drug
delivery systems are focused on two main goals: to
enhance manufacturing processes in response to the
need for reducing energy consumption, emissions,
wastes and risks; to innovate the functionality of
new formulations using biocompatible materials1,2,3.
Microencapsulation of active molecules is the man-
ufacturing technique that seems to better respond to
the requirements above as is shown by the continu-
ous development of new technologies, both in aca-
demic and industrial fields. In 2002, over 1000 pat-
ents were filed concerning various microencapsula-
tion processes4. Relevance of encapsulation tech-
niques consists in the effectiveness to protect many
kinds of active molecules (drugs, gene, anticancer
chemical drugs, vitamins and proteins) through
their envelopment in suitable carriers. By this way,
the overcoming of serious problems associated to
poor stability in physiological environments and
low absorption of many drugs and to their con-
trolled release is achieved.
Microencapsulation processes can be per-
formed by both physical-chemical and mechanical
processes5,6,3; all of them sharing the following fun-
damental steps: incorporation of bioactive com-
pounds; droplets formation; solvent removal;
microparticles harvest and stabilizing treatment7,8.
The suitable technique is selected on the bases of
the polymer nature, the desired particles size and
the chemical features of drug, with a special con-
cern to the drug solubility in the polymeric mate-
rial9.
Among the mechanical processes, micro-
encapsulation by ultrasonic assisted atomization is
characterized by several interesting features.
Briefly, small droplets of a uniform size may be
formed by feeding a fluid, at a controlled rate,
through a small orifice in the tip of a horn vibrating
ultrasonically in a longitudinal mode10 (ultrasonic
frequency allowed: 18–100 kHz). Vibration energy
causes formation of liquid threads and then of drop-
lets. Many literature references report studies that
explain the liquid disintegration by ultrasonic
mechanism11,12; cavitation and capillary wave
mechanisms theories are the most accredited13. Re-
cent popularity of the ultrasonic atomization can be
mainly attributed to its ability to produce drops of
small size and low inertia since it works involving
low velocities. This feature allows reducing the en-
ergy request respect to the more conventional atom-
ization systems (nozzle atomizers, two fluid atom-
izers), the volume of apparatuses (compact equip-
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ment) and the mechanical stress of feed avoiding
deactivation of bioactive substances.
In our previous works14,15 alginate polymers
were tested to produce microencapsulated pharma-
ceutical formulations by ultrasonic atomization.
The impact of physico-chemical properties of liq-
uids (flow rate, viscosity, density and surface ten-
sion) and of operating parameters (amplitude and
power of ultrasound) on the droplets size distribu-
tion and the role of transport phenomena in drug re-
lease kinetics were analyzed. In this work, chitosan
is selected to encapsulate a model active molecule
because it shows, as many carbohydrate polymers,
interesting features as biocompatible carrier for
drug release systems production.
Chitosan is a natural cationic polysaccharide
composed of glucosamine and N-acetyl-glucosamine
residues derived from partial deacetylation (degree
deacetylation, DD, performance) of chitin, which
is generally obtained from crustacean shells
(Fig. 1). Chitosan, being a cationic polysaccharide
in neutral or basic pH conditions, contains free
amino groups and is hence insoluble in water.
In acidic pH, amino groups can undergo proto-
nation, thus making chitosan soluble in water. Usu-
ally 1–3% aqueous acetic acid solutions are used
to solubilize it16,17. Chitosan presents features that
make it useful for preparation of drug encapsulating
microparticles. These include: ability to control
the release of active agents; possibility of avoiding
the use of organic solvents since it is soluble
in aqueous acidic solution; easiness of cross-link-
ing, being a linear polyamine containing a
number of free amine groups that are readily avail-
able for this purpose; increased residence time at
the site of absorption due to its mucoadhesive char-
acter16.
Chitosan-based particulate systems are de-
signed for pharmaceutical and biomedical applica-
tions. Some of them are:
– colon targeted drug delivery, since chitosan
can be biodegraded by colonic bacterial flora and
has mucoadhesive character (to prevent drug loss at
stomach and small intestine, thereby facilitating
quantitative drug delivery to the colon, chitosan
microparticles have to be coated by enteric materi-
als, such as Eudragit)18;
– bioadhesive dosage forms for mucosal ad-
ministration (ocular, nasal, buccal, gastro-enteric
and vaginal-uterine therapy);
– gene therapy. Chitosan could ionically inter-
act with the negatively charged DNA and forms
polyelectrolyte complexes, where DNA becomes
better protected against nuclease degradation, lead-
ing to better transfection efficiencies16,19;
– drug targeting to tumors. In fact, tumor tis-
sues exhibit lower pH (varying from 5.7 to 7.8 de-
pending on tumor histology and volume) than pH
of body tissue and of blood, which are around 7.418.
Detailed reviews of new developments on
chitosan-based bioapplications are reported in
Agnihotri et al.,16 and Dash et al.,20. On the micro-
encapsulation of active molecules in chitosan poly-
mer by ultrasonic assisted atomization several re-
searches are reported in Albertini et al.21, Klay-
pradit et al.22, Pamujula et al.23
Aims of this work were the production of fine
drug-loaded particles produced by ionic reticulation
of droplets obtained by ultrasonic atomization and
the study of their drug release properties. In particu-
lar, the data are used to estimate the PNMS (Poly-
meric Network Mesh-Size) to clarify its role in con-
trolled drug release, and the relationships holding




Chitosan (CS) (CAS no. 9012-76-4, medium
molecular weight, DD 75–85%) and B12 vitamin
(B12) (Sigma Aldrich, CAS no. 68–19–9) (Fig. 2)
were purchased from Sigma Aldrich s.r.l., Milano
IT and were used without further purification treat-
ments.
Acetic acid (AcA) (CAS no. 64-19-7) was used
to prepare water solution of chitosan (acidifying
agent); sodium tripolyphosphate (TPP) (CAS no.
7758-29-4, purity  98%) and hydrochloric acid
(CAS no. 64-19-7) were used in water solutions as
cross-linking and acidifying agents, respectively;
hydrochloric acid, sodium hydroxide (CAS no.
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F i g . 1 – Chitosan structure and prevalent kinds of reticula-
tion: by tripolyphosfate ionic crosslinking (a, at
low pH); by deprotonation (b, at high pH)26
1310-73-2) and potassium dihydrogen phosphate
(CAS no. 7778-77-0) were used as buffer solution
components. All the listed products were purchased
from Sigma Aldrich s.r.l., Milano IT.
Methods
Chitosan/B12 solution preparation. Several
batches of CS/B12/water solutions were prepared
by adding first B12 powders, 0.2 % w/v, in acidu-
late distilled water (by 1% v/v of AcA), then after a
gently mixing, 1% w/v of CS powders were added.
The preparing method was performed at room con-
dition; mixing was prolonged until obtaining a ho-
mogeneous solution.
Crosslinking solution preparation. TPP pow-
ders, 5 % p/v, were dissolved in distilled water to ob-
tain a solution with initial pH of 9 ca. Since better
reticulation conditions are achieved at low pH, drops
of hydrochloric acid were added to reach pH 3.
Chitosan/B12 particles production and charac-
terization. Chitosan ionic gelation, i.e the complexa-
tion between oppositely charged macromolecules to
give a network structure (reticulating process), is
the method that has attracted the greatest attention
in the gel-sphere preparation for the mild-condition
of the process and for its simplicity16,24. Further-
more, the ionic gelation method is characterized by
a reversible physical crosslinking due to electro-
static interaction instead of a chemical crosslinking,
and thus it can be applied avoiding possible toxicity
of reagents. Briefly, in this study, the ionic gelation
method was applied as follows: chitosan was dis-
solved in aqueous acidic solution to obtain positive
charges on polymeric chains (NH3
+ groups by
amine protonation). This solution was then added
within the tripolyphosphate solution (where
–P3O105– groups were contained). Due to the
complexation between oppositely charged species,
chitosan undergoes ionic gelation and precipitates
to form spherical particles. It is worth to note that
the ionic gelation performance is affected from the
degree of deacetylation (DD) and the molecular
weight (Mw) of the chitosan . High percentage of
DD allows increases of free amino groups, conse-
quently more strong crosslinkings are obtainable
even if, in general, TPP/CS microparticles have in-
trinsically poor in mechanical strength that is one of
the limits in their usage in drug delivery16.
In this work, two kinds of particles, both consid-
ered as matrix structures, were produced using the
home-made apparatus sketched in Fig. 3. It consists
by a VCX 130 PB ultrasonic processor (130 W,
20 kHz, Sonics & Materials Inc., CT, USA) and a
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Alternative name: cyanocobalamin
Molecular formula: C63H88CoN14O14P
Molecular weight: 1355.37 uma
Commercial form: dark red crystalline powder
Stokes radius (rStokes): 0.86 nm
Water solubility: high
Diffusivity (in water at 37°C): 3.8 · 10–10 m2/s
F i g . 2 – B12 structure and its some properties
F i g . 3 – Sketch of the home-made apparatus assembled and used to produce chitosan/B12 particles
standard tip (sonotrode, i.e. a steel channel with in-
ner diameter of 2.3 · 10–3 m) for low atomization rate
(up to 1 mm3/s), code VC 4020 (50 W, 20 kHz,
Sonics & Materials Inc., CT, USA) as sources of ul-
trasonic vibration and atomizer, respectively. Feed
solution is delivered to the sonotrode by a peristaltic
pump (Velp Scientifica Italia, Usmate, MI, ITALY).
The produced drops are collected in the reticulating
bulk placed on a magnetic stirrer. The distance be-
tween the atomizer tip and the reticulating solution is
maintained at approximately 2 cm.
In particular, several batches of millimetric par-
ticles were obtained by dripping method, i.e. keeping
the ultrasonic generator off (Fig. 3, US off). By this
way was reproduced the most common technique
used to produce beads in reticulating bulk. Micro-
particles of CS/B12 were produced activating the
ultrasonic generation (Fig. 3, US on). In Table 1 the
main operative parameters were summarized.
Both kinds of particles were obtained by
crosslinking phenomena between chitosan poly-
meric chains and tripolyphosphate groups. After a
given time of exposure to reticulation, rubbery par-
ticles were obtained. Then, they were separated by
a filtration process, washed by phosphate buffer so-
lution, photographed (by Canon digital camera,
IXUS 850 IS, by Leica digital camera DFC 280
mounted on optical microscope Leica Microsystems
DM-LP, Wetzlar, GERMANY) and subjected to
diameter measurements by image analysis (using
the public domain software ImageJ 1.40g, Wayne
Rasband, National Institutes of Health, USA, freely
available at http://rsb.info.nih.gov/ij/). Finally, pro-
duced particles were stabilized by convective dry-
ing in oven at 50°C until reaching constant weight.
Moisture content of fresh and dried particles was
assayed by a moisture balance (OHAUS mod
MB45, OHAUS Europe, Nänikon, SWISS).
All kinds of produced particles were subjected
to dissolution tests to evaluate the yield of encapsu-
lation, the amount of drug loading, and the release
kinetics under physiological conditions. In particu-
lar, the dissolution tests were carried out putting
given amounts of particles in a beaker where stirred
buffer solution at pH 7.4 was kept at 37°C. B12
in dissolution bulks was assayed by spectrophoto-
metric analysis (Lambda 25 UV/VIS Spectrometer,
PerkinElmer, Waltham, MA, USA) at 361 nm.
Since particles were produced in a low amount per
test, the conventional USP Apparatus 2 cannot be
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T a b l e 1 – Selected operative parameters
Droplet production
Operative parameters
By dripping technique By ultrasonic assisted atomizazion
Droplets production
Chitosan concentration 1% w/v 1% w/v
B12 load 0.2 % w/v 0.2 % w/v
Feed solution rate 4.8 mL/min 4.8 mL/min
Ultrasonic amplitude -- 98%
Particles production
Tripolyphosfate solution conc. 1% w/v 1% w/v
Volume reticulation solution 100 ml 100 ml
Reticulating solution pH 3 3
Stirring condition 150 rpm 150 rpm
Reticulation time 3 min 3 min
Separation technique: filtration yes yes
Washing medium (phosphate buffer pH 7.4) yes yes
Particles characterization
diameter, encapsulation efficiency,
drug load, release properties
diameter, encapsulation efficiency,
drug load, release properties
Particles stabilization






used because it requires a large volume of dissolu-
tion and then diluted solution for which UV–vis
spectrophotometry method was proved to be inac-
curate to assay the B12 releases. All the experimen-
tal tests were performed at minimum in triplicate.
Results and discussion
Process parameters setting. The production of
B12 loaded microparticles by ultrasonic atomiza-
tion was preceded by several preliminary activities
focused on the setting of the suitable operative pa-
rameters to be adopted. Since many factors affect
both drug entrapment efficiency and drug release
properties (process parameters and materials prop-
erties), polymer concentration, feed solution rate,
concentration, pH and bulk quantity crosslinking
solution, reticulation time and stirring velocity were
investigated. To better observe the influence of the
above listed parameters millimetric particles were
produces using the apparatus showed in Fig. 3. with
the ultrasonic generator off (dripping method).
Generally, a low concentration of chitosan cor-
responds to a low encapsulation efficiency and a
poor particles consistence; however, at higher con-
centrations, chitosan forms highly viscous solu-
tions, which are difficult to process17,25. For this
reason an optimum of 1% w/v of chitosan concen-
tration was selected. Feed solution rate was chosen
to guarantee a full and stable atomization at condi-
tions of ultrasonic generator on (selecting also the
amplitude percentage of the ultrasonic signal).
Crosslinking solution concentration has an effect on
particle strength even if its effect must be discussed
together with the solution pH values. At low pH
(typically 3), phosphoric ions are predominantly in-
volved in the crosslinking. At high pH (typically 9)
both the OH– and phosphoric ions are present, and
compete with each other to interact with the –NH3
+
sites of chitosan (OH– ions are linked to the amino
group by deprotonation, see sketch in Fig. 1). Start-
ing from swelling and elemental measurements, and
SEM investigation Bhumkar et al.,26 found that
chitosan crosslinked structure obtained at pH 3 had
a higher density (and lower porosity) then those re-
ticulated at pH 9. On the bases on literature studies,
in this work to obtain particles with more consis-
tence (to allow an easy separation step), the reticu-
lation solution was acidified by hydrochloric acid
until pH 3. The reticulation volume was fixed to
100 mL to guarantee an opportune bulk stirring ve-
locity. This latter parameter was optimized to effi-
ciently disturb the surface of the liquid bulk so as to
avoid any accumulation of drops on liquid surface
that could obstruct the droplets entrance into the re-
ticulating bulk. However, high stirring velocity had
effect on morphology as this could lead to prolate
or disrupted particles. Several tests to define the op-
portune crosslinking time were, at last, carried out.
Prolonged times were revealed to be non-signifi-
cant to obtain an increase in consistence particles.
They rather allowed high losses of loaded active
molecule in the crosslinking bulk. Thus, 3 minutes
were selected as the overall reticulation time: i.e.
the time was counted from the start of dripping or
atomization processes, extended at 2 min, and after
1 more minute at feed solution switched off. In Ta-
ble 1 the selected operative parameters were sum-
marized.
Particles features and release properties. In
Fig. 4 photos of both fresh millimetric and micro-
particles were shown. In Table 2 main properties of
both kinds of particles were reported. Millimetric
(mean diameter: 5.40 mm ± 0.40) and micropartic-
les (mean diameter: 790 m ± 0.38) were character-
ized by spherical morphologies and polymeric-shell
liquid-core structures. Diameters and shell thick-
ness were observed and measured by imagine anal-
ysis of digital photos.
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F i g . 4 – Fresh millimetric particles and microparticles of
chitosan/B12
Encapsulation efficiency (EE) of both kinds of
loaded particles was assayed by destructive dissolu-
tion tests performed putting given amounts of fresh
washed particles in known volumes of buffer solu-
tion. Entrapped B12 (mg) was then measured by
spectrophotometric method. The theoretical B12
mass was calculated starting from the values of B12
concentration in feed solution and the used feed so-
lution volume both in dripping and atomization










In millimetric particles the EE assayed was of
66% (± 5.1) whereas in microparticles 12% (± 0.53)
was determined. These different performances were
due to the different size (see different surface areas)
of particle exposed to reticulation bulk where large
amounts of B12, especially in microparticles
batches, were measured.
Drug content (DC) of both kinds of loaded par-
ticles was also assayed (starting from the ratio be-
tween values of the effective B12 encapsulated
mass and the dried total mass per 100) achieving
3.7 % (± 0.21) and 0.91 % (± 0.17) for millimetric-
and micro- particles, respectively.
In Fig. 5 the B12 release profiles from fresh
chitosan particles were reported. They were shown
a very fast B12 release rate: for both the two kinds
of particles after 30 minutes more than of 70% of
active molecule was transferred in the dissolution
bulk. Moreover erosion phenomena were not
observed. All this, together to the high losses of
B12 in the reticulating bulk (or otherwise the low
EEs achieved) suggested that diffusion was the
dominant transport phenomenon through the shell
of particles. Despite relative large size and mole-
cular weight of B12 molecule (rStokes = 0.86 nm,
Mw ~ 1400 uma) it was appeared reasonable to ex-
tent to chitosan reticulated structure some hypothe-
ses and study approaches developed on the diffu-
sion of small molecules in alginate crosslinked
gel15,2. In particular, polymeric network mesh-size
(PNMS) was the first imputed factor placed under
investigation.
PNMS estimation. To evaluate the release kinet-
ics and the influence of the shell-core structure of
chitosan particles on transport phenomena, a simple
model of the drug release has been proposed. A
number N of small particles of external radius a (and
thus of volume V a1
34 3 ( / ) ) were immersed in a
volume V2 of dissolution medium, initially
drug-free, C tA
0 0 0( ) ,  stirred and thermostated.
The particles have a shell of thickness , and are
practically all of the same size (mono-disperse distri-
bution is usually achieved both by dripping and by
ultrasonic assisted atomization). The situation is de-
picted in Fig. 6. In the inset, size and concentration
of the drug (component “A”) in the core, CA
I, in the
shell, CA
P, and in the dissolution medium, CA
0, are re-
ported. The resistance to the transport is hypothe-
sized to be localized only in the shell, therefore the









The two mass (drug) balances in the N particles
and in the dissolution medium V2 are:
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F i g . 5 – B12 release profiles from fresh chitosan particles
(the error bars refer to the standard deviation SD)
T a b l e 2 – Main properties of fresh and dried particles ob-























3.75 mm ± 0.58
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The two ODEs (3) can be analytically solved,
making also use of eq. (2). The evolution of the


















































An estimate of the initial drug loading concen-
tration, CA0
I, could be easily obtained knowing that
the initial drug (CA0
INV1), at the steady state, will be
present in the dissolution medium (concentration
equal to CASS
0, mass equal to CASS
0V2) in equilibrium
with some drug still confined into the micro-
particles themselves (CASS
0NV1, the concentration in
the outer phase, CASS
0, being the same of the con-
centration inside the microparticles, CASS
I). There-














The raw release data, i.e. concentration of the
B12 in the dissolution medium from which data in
Fig. 5 have been calculated, can be taken as the ba-
sis for the depicted analysis. Once all the parame-
ters (a, N, d, CASS
0) are known or estimated (see
Table 3), the fitting of eq. (4) to the experi-
mental data allows to calculate the diffusivity of
B12 through the polymeric shell (D, which is the
only unknown in eq. (4) once the evolution of
B12 concentration in the dissolution medium is
known). Table 3 reports the values calculated,
by this way, for the diffusivity in the two systems:
D = 2.18 · 10–10 m2/s for particles obtained by drip-
ping and D = 1.06 · 10–10 m2/s for particles obtained
by ultrasound assisted atomization. The two tech-
niques, beyond to give particles of different size,
could produce different microstructures, either be-
cause of the effects of the ultrasound on the gel net-
work, and because of the kinetics (and the extent)
of the reticulation which is affected by the size of
the produced droplets.
The diffusivity of B12 in water is known to be
D0 = 3.80 · 10
–10 m2/s, and the Stokes (hydrodynamic)
radius of the molecule is rStokes = 0.86 nm. The ratio
D/D0 for the two systems therefore assumes the val-
ues Ddripping/D0 = 0.574 and Datomization/D0 = 0.278.
Lustig and Peppas 27 proposed, and Amsden 28 exten-
sively tested, a relationship obtained starting from




























In which rs is the Stokes radius,  is the poly-
mer volume fraction  polymer mass fraction 
solid fraction = 0.07 (particles mean moisture: 0.93) of
particles, and  is the network mesh size. According to
Lustig and Peppas, the coefficient Y can be taken as
unity, and this allow to calculate radius mesh size of
dripping = 2.3 nm and of atomization = 1.2 nm. Both
values resulted larger than the B12 Stokes radius.
Drying process and its effects. As reported in
section Experimental, fresh chitosan particles were
stabilized by drying convective treatments. The
main characteristics of the dried systems achieved
were shown in Table 2. Millimetric particles were
subjected to a greater volumetric shrinkage than the
microparticles (66 % vs 53 %); on the contrary, the
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F i g . 6 – Schematic of the drug release tests and of the
main hypotheses of the model-based analysis
















dripping 2.700 50 250 119.2 2.18 · 10–10 0.574 2.3
ultrasonic assisted atomization 0.395 5300 10 40.0 1.06 · 10–10 0.278 1.2
residual moisture contents determined was higher in
microparticles than in millimetric particles. As hy-
pothesized in the Mesh size estimation paragraph, a
different structural arrangement occurred in the par-
ticles formation under the different process condi-
tions, so the same water equilibrium contents could
be not achieved.
In Fig. 7 the B12 release profiles from dried
chitosan particles were reported. As can be seen,
drying process did substantially not affect the re-
lease kinetics. Indeed, fast B12 diffusion was ob-
served for both kinks of dried particles (the 80% of
B12 load was released in about 30 minutes). In par-
ticular, due to the larger exchange area, loaded
microparticles exhibited a B12 percentage releases
over 70% within the first 10 minutes. With respect
to the B12 release profiles assayed starting from
fresh particles, a little delay in the B12 diffusion
was observed. It was attributed to the time required
to wet and plasticize the chitosan reticulated chains.
Thus, the applied drying conditions, although lead-
ing a volumetric shrinkage by more than 50%,
globally did not affect the release properties of
chitosan/B12 particles.
Conclusions
In this work the ultrasonic assisted atomiza-
tion was applied as an encapsulation technique
to obtain B12 loaded particles of chitosan. By
this technique, funded on ionic gelation method,
spherical microparticles of chitosan / B12 of
about 600 micron (after drying treatment) were
achieved.
Release tests demonstrated that the reticulation
(ionic gelation) process was the key step in the
structure particles formation, that, in turn, had a
crucial role on the loaded particles release proper-
ties. In particular, the observed low encapsulation
efficiency, low load and B12 fast release for both
the two kinds of produced particles, i.e, millimetric
and micro- spheres, suggested the presence of large
pore sizes of the gel (PNMS) which take place ac-
cording to the characteristics of used chitosan (de-
gree of deacetylation) and the pH of the
crosslinking environment. On the basis of correla-
tion available in literature, an estimation of PNMS
was done, obtaining radius of mesh sizes dripping =
2.3 nm and atomization = 1.2 nm more larger than the
B12 Stokes radius (rStokes = 0.86 nm), confirming
the above proposed hypotheses.
The main address derived from this work is
that a controlled release from loaded chitosan parti-
cles can be achieved only tuning the polymeric net-
work’s structure. To this purpose new manufactur-
ing protocols could be tested starting from chitosan
features (DD, molecular weight) to reticulating con-
ditions and stabilizing treatments that can affect
structural properties such as crosslinking
coadjuvant agents or thermal curing.
ACKNOWLEDGEMENTS
This work has been supported by the Italian
Ministry of Education (PRIN 2008 – 2008HCAJ9T).
R e f e r e n c e s
1. Dalmoro, A., Barba, A. A., Lamberti, G., d’Amore, M., Eu-
ropean Journal of Pharmaceutics and Biopharmaceutics 80
(2012) 471–477
2. Dalmoro, A., Barba, A. A., Lamberti, G., Grassi, M.,
d'Amore, M., Advances in Polymer Technology (2012) in
press
3. Tran, V.-T., Benoît, J.-P., Venier-Julienne, M.-C., Interna-
tional Journal of Pharmaceutics 407 (2011) 1–11
4. Gouin, S., Trends in Food Science & Technology 15
(2004) 330–347
5. Benita, S., Microencapsulation: methods and industrial ap-
plications, Informa HealthCare, 2006
6. Jyothi, N. V. N., Prasanna, P. M., Sakarkar, S. N., Prabha,
K. S., Ramaiah, P. S., Srawan, G., Journal of micro-
encapsulation 27 (2010) 187–197
7. Freitas, S., Merkle, H., Gander, B., Journal of Controlled
Release 102 (2005) 313–332
8. Lyons, S., Wright, S., US6331317, (2003)
9. Ré, M., Biscans, B., Powder Technology 101 (1999) 120–133
10. Ensminger, D., Stulen, F., Ultrasonics: data, equations, and
their practical uses, CRC Press, 2009
11. Rajan, R., Pandit, A., Ultrasonics 39 (2001) 235–255
12. Mason, T. J., Ultrasonics Sonochemistry 10 (2003) 175–179
13. Liu, H., Science and engineering of droplets: fundamentals
and applications, William Andrew, 2000
352 A. A. BARBA et al., Controlled Release of Drugs from Microparticles Produced …, Chem. Biochem. Eng. Q. 26 (4) 345–353 (2012)
F i g . 7 – B12 release profiles from dried chitosan particles
(the error bars refer to the standard deviation SD)
14. Barba, A. A., d'Amore, M., Cascone, S., Lamberti, G.,
Titomanlio, G., Chemical Engineering and Processing:
Process Intensification 48 (2009) 1477–1483
15. Cascone, S., Lamberti, G., Titomanlio, G., Barba, A. A.,
d’Amore, M., Drug development and industrial pharmacy
38 (2012) 1486–1493
16. Agnihotri, S. A., Mallikarjuna, N. N., Aminabhavi, T. M.,
Journal of Controlled Release 100 (2004) 5–28
17. Sinha, V., Singla, A., Wadhawan, S., Kaushik, R., Kumria,
R., Bansal, K., Dhawan, S., International Journal of Phar-
maceutics 274 (2004) 1–33
18. Park, K., Yeo, Y., US6767637, (2003)
19. Rudzinski, W. E., Aminabhavi, T. M., International Journal
of Pharmaceutics (2010)
20. Dash, M., Chiellini, F., Ottenbrite, R. M., Chiellini, E.,
Progress in Polymer Science 36 (2011) 981–1014
21. Albertini, B., Passerini, N., Rodriguez, L., Journal of Phar-
macy and Pharmacology 57 (2005) 821–829
22. Klaypradit, W., Huang, Y., LWT-Food Science and Tech-
nology 41 (2008) 1133–1139
23. Pamujula, S., Graves, R. A., Moiseyev, R., Bostanian, L.
A., Kishore, V., Mandal, T. K., Journal of Pharmacy and
Pharmacology 60 (2008) 283–289
24. Bodmeier, R., Oh, K.-H., Pramar, Y., Drug development
and industrial pharmacy 15 (1989) 1475–1494
25. Park, J., Saravanakumar, G., Kim, K., Kwon, I., Advanced
drug delivery reviews 62 (2010) 28–41
26. Bhumkar, D. R., Pokharkar, V. B., AAPS PharmSciTech 7
(2006) 138–143
27. Lustig, S. R., Peppas, N. A., Journal of Applied Polymer
Science 36 (1988) 735–747
28. Amsden, B., Macromolecules 31 (1998) 8382–8395
A. A. BARBA et al., Controlled Release of Drugs from Microparticles Produced …, Chem. Biochem. Eng. Q. 26 (4) 345–353 (2012) 353
